The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects

Lehmann, 1942, Hypoprothrombinaemia produced by methylene-bis-(hydroxycoumarin), its use in thrombosis, Lancet, 1, 318, 10.1016/S0140-6736(00)57768-X

Allen, 1942, A preparation from spoiled sweet clover (3, 3′-methylene-bis-(4-hydroxycoumarin)) which prolongs coagulation and prothrombin time of the blood: a clinical study, JAMA, J Am Med Assoc, 120, 1009, 10.1001/jama.1942.02830480013004

Hirsh, 1998, Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range, Chest, 114, 445S, 10.1378/chest.114.5_Supplement.445S

Anonymous. Biverkningsnytt. Rekordantal rapporter 1992. Läkartidningen 1993;90:2533–4.

Hauptmann, 1999, Synthetic inhibitors of thrombin and factor Xa: from bench to bedside, Thromb Res, 93, 203, 10.1016/S0049-3848(98)00192-3

Elg, 1999, Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat, Thromb Res, 94, 187, 10.1016/S0049-3848(98)00213-8

Elg, 1997, The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis, Thromb Haemostasis, 78, 1286, 10.1055/s-0038-1657729

Gustafsson, 1998, Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes, Thromb Haemostasis, 79, 110, 10.1055/s-0037-1614245

Metha, 1998, Melagatran, an oral active site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery, J Cardiovasc Pharmacol, 31, 345, 10.1097/00005344-199803000-00003

Eriksson, 1997, Antithrombotic effect of two low molecular weight thrombin inhibitors and a low molecular weight heparin in a caval vein thrombosis model in the rat, Thromb Haemostasis, 78, 1404, 10.1055/s-0038-1665419

Mattsson, 1997, Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in the canine model of coronary artery thrombolysis, Fibrinolysis Proteolysis, 11, 121, 10.1016/S0268-9499(97)80056-2

Eriksson, 1999, Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT, Thromb Haemostasis, 81, 358, 10.1055/s-0037-1614477

Bredberg, 1999, Pharmacokinetics of melagatran, a novel thrombin inhibitor, in healthy volunteers following intravenous, subcutaneous and oral administration, Blood, 94, 110

Sanderson, 1999, Small, noncovalent serine protease inhibitors, Med Res Rev, 19, 179, 10.1002/(SICI)1098-1128(199903)19:2<179::AID-MED4>3.0.CO;2-5

Misra, 1994, Argatroban analogs: synthesis, thrombin inhibitory activity and cell permeability of aminoheterocyclic guanidine surrogates, Bioorg Med Chem Lett, 4, 2165, 10.1016/S0960-894X(00)80064-5

Sanderson, 1998, L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor, Bioorg Med Chem Lett, 8, 817, 10.1016/S0960-894X(98)00117-6

Lee, 1998, Benzylamine-based selective and orally bioavailable inhibitors of thrombin, Bioorg Med Chem Lett, 8, 2563, 10.1016/S0960-894X(98)00456-9

Ambler, 1998, The discovery of orally available thrombin inhibitors; studies towards the optimisation of CGH1668, Bioorg Med Chem Lett, 8, 3583, 10.1016/S0960-894X(98)00640-4

Saitoh, 1999, Improvement of the intestinal absorption of a peptidomimetic, boronic acid thrombin inhibitor possibly utilizing the oligopeptide transporter, Pharm Res, 16, 1786, 10.1023/A:1011989504054

Antonsson KT, Bylund RE, Gustafsson ND, Nilsson NIO. Trypsin-like protease-inhibiting peptide derivatives, their synthesis and therapeutic use. Patent application WO 94/29336-A1.

Antonsson T, Gustafsson D, Hoffman K-J, Nyström J-E, Sörensen H, Sellén M. Preparation of peptide derivatives as prodrug of thrombin inhibitors. Patent application WO 97/23499-A1.

Schill, 1983, 1

1993

Artursson, 1993, Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments, Pharm Res, 10, 1123, 10.1023/A:1018903931777

Eriksson, 1999, Single and repeated oral dosing of H 376/95, a prodrug to the direct thrombin inhibitor melagatran, to young healthy male subjects, Blood, 94, 101

Müller, 1997, Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men, Circulation, 96, 1130, 10.1161/01.CIR.96.4.1130

Wittke, 1999, Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers, Br J Clin Pharmacol, 47, 521, 10.1046/j.1365-2125.1999.00931.x

Eriksson, 2000, Methro II: dose–response study of the novel oral, direct thrombin inhibitor, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip or knee replacement, Haemostasis, 30, OC38